U.S., Nov. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07933471) titled 'Total Neoadjuvant Immunotherapy Plus Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma' on Nov. 06.
Brief Summary: This study is for people with locally advanced adenocarcinoma of the stomach or of the junction between the stomach and esophagus (gastroesophageal junction adenocarcinoma) that can be removed by surgery. Serplulimab (an anti-PD-1 antibody) has been approved in China for use around the time of surgery in this type of cancer. This study will evaluate a treatment approach called total neoadjuvant therapy, in which all planned immunotherapy plus chemotherapy is given before surgery.
Abo...